​

The company believes that ARMS-I uses a dual action approach to potentially prevent and treat Upper Respiratory Infections: 

 

1. A microbe-impermeable barrier is applied at the oropharynx, a gateway to the pathogenesis of vURTI’s, therefore potentially blocking the ability for pathogens to reach mucosal tissue and begin the infection cycle

 

2. The barrier is infused with an antiviral which is believed to be resistant to antigenic drift and viral mutation which has the potential to kill pathogens that come into contact with the barrier, thus intensifying the effect of the barrier action 

​

​

                                                          Illustration of Theorized ARMS-I Mechanism of Action